Cannabidivarin

Cannabidivarin (CBDV, GWP42006) is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry) of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH₂ units).

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.<ref>Template:Cite journal</ref><ref name="HilligMahlberg">Template:Cite journal</ref><ref>Template:Cite journal</ref>

CBDV demonstrated anticonvulsant in rodent models in a single published study.<ref>Template:Cite journal</ref> It was identified for the first time in 1969 by Vollner et al.<ref>Template:Cite journal</ref>

Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Isomerism). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)<ref name="GWPharm18">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.<ref>Template:Cite journal</ref> GW has begun several Phase-2 trials for adult epilepsy,<ref>Template:Cite press release</ref> for childhood epilepsy and for Prader-Willi Syndrome.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

See also

• List of investigational analgesics

External links

• Erowid Compounds found in Cannabis sativa
• Cannabidivarin

{{#invoke:Navbox|navbox}} Template:Transient receptor potential channel modulators